Skip to main content
Testing version — LOERadar is in active testing. Features and data may change.
LOERadar
LOE
Radar
Hub
News
Changes
Search
Log in
Get Started
SUNLENCA (LENACAPAVIR SODIUM) | LOERadar
Viewing data from:
Latest
2026-07-01
2026-06-01
2026-05-01
2026-04-01
2026-03-28
2026-02-17
2026-02-10
2025-12-14
2025-02-26
2025-01-25
2024-11-08
2023-07-23
2023-06-15
2023-05-13
2023-01-26
2022-11-22
2022-10-28
2022-09-29
2022-07-09
2022-06-29
2022-04-08
2022-03-09
2021-12-28
2021-05-05
2021-03-12
2020-12-22
2020-11-12
2019-12-14
2019-09-15
SUNLENCA
NDA
Get alerts
LENACAPAVIR SODIUM | N215974 | GILEAD SCIENCES INC
1 strength
5 unique patents
1 unique exclusivity
Patents
SEC Intel
Revenue
PTAB
Reexams
Litigation
Petitions
Trials
DMF
Approvals
Label
Products
Patent Timeline
5 unique patents, 1 exclusivity by expiration date
Active (5)
Today
Exclusivity
2026
2027
2028
2029
2030
2031
2032
2033
2034
2035
2036
2037
2038
2039
2040
2041
2042
Today
9951043
Feb. 28, 2034
10071985
Aug. 17, 2037
10654827
Aug. 17, 2037
11267799
Aug. 16, 2038
11944611
Aug. 28, 2041
NCE
Dec. 22, 2027
PTAB Proceedings
No IPR/PGR/CBM challenges found at the Patent Trial and Appeal Board
Hatch-Waxman Litigation
No ANDA patent litigation cases (NOS 835) matched from PACER
Citizen Petitions
No FDA citizen petitions matched from Regulations.gov
Products (1)
#001 — EQ 300MG BASE
RLD
5 patents
1 exclusivity
▴
TABLET;ORAL | Approved: Dec 22, 2022
Patents (5)
Patent #
Expiration
PED
Drug Substance
Drug Product
Use Code
Delist
9951043
Feb 28, 2034
—
Yes
Yes
U-3507
IN COMBINATION WITH OTHER ANTIRETROVIRAL(S), FOR THE TREATMENT OF HIV-1 INFECTION IN HEAVILY-TREATMENT EXPERIENCED ADULTS WITH MULTIDRUG RESISTANT HIV-1 INFECTION
—
10071985
Aug 17, 2037
—
Yes
Yes
—
—
10654827
Aug 17, 2037
—
—
—
U-3507
IN COMBINATION WITH OTHER ANTIRETROVIRAL(S), FOR THE TREATMENT OF HIV-1 INFECTION IN HEAVILY-TREATMENT EXPERIENCED ADULTS WITH MULTIDRUG RESISTANT HIV-1 INFECTION
—
11267799
Aug 16, 2038
—
Yes
—
—
—
11944611
Aug 28, 2041
—
—
—
U-3507
IN COMBINATION WITH OTHER ANTIRETROVIRAL(S), FOR THE TREATMENT OF HIV-1 INFECTION IN HEAVILY-TREATMENT EXPERIENCED ADULTS WITH MULTIDRUG RESISTANT HIV-1 INFECTION
—
Exclusivities (1)
Code
Date
Status
NCE
Dec 22, 2027
Active